CARB-X

LimmaTech Biologics is a clinical-stage biotech company focused on developing vaccines to prevent life-threatening diseases. It specializes in creating bioconjugate vaccines through innovative techniques such as glycoengineering and protein glycosylation, which improve the efficiency of vaccine development and address challenges associated with traditional chemical conjugation methods. The company's proprietary self-adjuvanting and multi-antigen vaccine platforms target microbial infections that are increasingly resistant to existing treatments. LimmaTech Biologics is dedicated to expanding its pipeline, aiming to provide effective solutions for infectious diseases that currently have limited treatment options. Through its research and development efforts, the company seeks to enhance healthcare outcomes by delivering tailored vaccines for specific pathogens.

Visby Medical, Inc. is a diagnostics company based in San Jose, California, specializing in the development of polymerase chain reaction (PCR)-based diagnostic tests for infectious diseases. Founded in 2008 and formerly known as Click Diagnostics Inc., the company creates single-use, handheld testing kits that provide instrument-free results for various conditions, including COVID-19 and sexually transmitted infections. Visby Medical aims to redefine illness testing and treatment through a human-centric approach, focusing on accuracy and user experience. In addition to its diagnostic products, the company offers a mobile health care platform that encompasses health information, risk assessment, electronic medical records, and remote medical advice services, catering to governments, NGOs, and private health providers.

Melio provides a quick and comprehensive blood test that detects all prevalent infections. Their technology allows for prompt and targeted therapy while also combating antibiotic resistance. Melio is headquartered in Santa Clara, California.

Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company based in Basel, Switzerland, that focuses on developing innovative therapeutic products in the fields of oncology and anti-infectives. The company offers isavuconazole, marketed under the brand name Cresemba, an antifungal drug used to treat invasive aspergillosis and mucormycosis. Additionally, Basilea provides ceftobiprole, an intravenous antibiotic for community and hospital-acquired pneumonia, which is also undergoing Phase III clinical trials for other serious bacterial infections. The company is actively developing several candidates, including Derazantinib, for intrahepatic cholangiocarcinoma, and BAL101553 and BAL3833, which target various tumor types and cancer pathways. Through its integrated research and commercial operations, Basilea aims to address the growing challenges of antibiotic resistance and the limitations of current treatment options.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company based in Basel, Switzerland, that focuses on developing innovative therapeutic products in the fields of oncology and anti-infectives. The company offers isavuconazole, marketed under the brand name Cresemba, an antifungal drug used to treat invasive aspergillosis and mucormycosis. Additionally, Basilea provides ceftobiprole, an intravenous antibiotic for community and hospital-acquired pneumonia, which is also undergoing Phase III clinical trials for other serious bacterial infections. The company is actively developing several candidates, including Derazantinib, for intrahepatic cholangiocarcinoma, and BAL101553 and BAL3833, which target various tumor types and cancer pathways. Through its integrated research and commercial operations, Basilea aims to address the growing challenges of antibiotic resistance and the limitations of current treatment options.

Helmholtz Institute for Pharmaceutical Research Saarland is a research institute that focuses on the development of pharmaceutical and natural product-based research for novel anti-infectives.

GlyProVac is focused on developing a glycoprotein-based vaccine aimed at preventing infections caused by Enterotoxigenic Escherichia coli (ETEC). Utilizing its proprietary BEMAP technology, the company identifies various O-linked protein glycosylations, which serve as potential targets for antimicrobial intervention. This innovative approach aims to enhance immune responses in individuals, thereby reducing the risk of ETEC infections. Through its research and development efforts, GlyProVac seeks to contribute to public health by addressing a significant cause of gastrointestinal disease, particularly in vulnerable populations.

Visby Medical, Inc. is a diagnostics company based in San Jose, California, specializing in the development of polymerase chain reaction (PCR)-based diagnostic tests for infectious diseases. Founded in 2008 and formerly known as Click Diagnostics Inc., the company creates single-use, handheld testing kits that provide instrument-free results for various conditions, including COVID-19 and sexually transmitted infections. Visby Medical aims to redefine illness testing and treatment through a human-centric approach, focusing on accuracy and user experience. In addition to its diagnostic products, the company offers a mobile health care platform that encompasses health information, risk assessment, electronic medical records, and remote medical advice services, catering to governments, NGOs, and private health providers.

Syntiron’s antigen discovery and purification technology targets the bacterial iron transport proteins that are critical for causing an infection.

Intravacc is a research and development organization with over 100 years of experience in vaccinology. The company specializes in the independent development of vaccines, taking them from initial concepts through to clinical phase I and II studies. Intravacc has a diverse product pipeline and holds various patents, reflecting its commitment to innovation in vaccine technology. Among its projects, the organization is developing vaccines to prevent infections caused by Neisseria gonorrhoeae, aiming to assist healthcare practitioners in treating patients effectively. Intravacc offers comprehensive solutions to optimize vaccine processes and technologies, facilitating the transition from discovery to late-stage clinical studies.

The Doherty Institute is a prominent research and education facility dedicated to advancing global health through the study and management of infectious diseases. It focuses on discovery research aimed at the prevention, treatment, and cure of these diseases. The institute offers a range of educational programs, including undergraduate and postgraduate courses, as well as professional development opportunities, aligning with its research themes in immunology, viral infectious diseases, host-pathogen interactions, antimicrobial resistance, public health, epidemiology, and genomics. By integrating research and clinical services, the Doherty Institute plays a crucial role in developing innovative strategies to combat infectious diseases and improve health outcomes worldwide.

Day Zero Diagnostics Inc. is an infectious disease diagnostics company focused on developing rapid, sequencing-based diagnostics that identify bacterial pathogens and their antibiotic resistance profiles. The company employs advanced technologies such as Blood2Bac, which enhances bacterial DNA recovery from clinical samples, and BacDetect, designed for the swift detection of bacterial DNA. Its Keynome ID algorithm classifies bacterial species, while Keynome g-AST utilizes machine learning for genomic antibiotic susceptibility testing. Additionally, Day Zero maintains MicrohmDB, a comprehensive database that integrates whole genome sequencing data with resistance and susceptibility profiles of clinically relevant pathogens. Founded in 2016 and based in Boston, Massachusetts, Day Zero aims to transform infectious disease diagnostics by providing complete diagnoses—including species identification and antibiotic resistance—within hours, significantly improving treatment outcomes and reducing costs associated with prolonged diagnostic processes.

Avails Medical, Inc. is an in vitro diagnostics company based in Menlo Park, California, focused on addressing antibiotic resistance and healthcare-associated infections. Founded in 2013, the company has developed an innovative electronic biosensor technology that enables rapid and accurate detection of infections across various bodily fluids. This technology provides real-time information on antibiotic sensitivity and resistance, allowing healthcare providers to optimize treatment at the point of prescription. Avails Medical's flagship product, eQuant, is a compact instrument that integrates a cuvette with an electrical sensor to analyze diluted blood samples. By facilitating diagnostic-guided therapy, the company's platform significantly reduces the time to treatment from days to minutes, thereby transforming the infection detection landscape and addressing a critical global health challenge.

Debiopharm Group is a biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. They develop their products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

Vaxcyte, Inc. is a biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases globally. The company’s lead candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine. Additionally, Vaxcyte is advancing VAX-XP, which targets emerging strains that contribute to invasive pneumococcal disease and antibiotic resistance. Other notable candidates include VAX-A1, designed to protect against Group A Streptococcus infections, and VAX-PG, a therapeutic vaccine aimed at treating periodontal disease caused by Porphyromonas gingivalis. Vaxcyte utilizes a proprietary cell-free protein synthesis platform that enables the creation of protein carriers and antigens, enhancing vaccine development beyond conventional methods. Founded in 2013 and headquartered in Foster City, California, the company was previously known as SutroVax, Inc. before rebranding in May 2020.

Accelerate Diagnostics, Inc. is an in vitro diagnostics company based in Tucson, Arizona, focused on addressing serious infections and the challenge of drug-resistant organisms. Established in 1982, the company specializes in the rapid identification and antibiotic susceptibility testing of infectious pathogens through its innovative Accelerate Pheno system. This platform is designed to analyze samples for both gram-positive and gram-negative organisms, as well as yeast, delivering results significantly faster than traditional methods. By utilizing a proprietary culture-free process that combines genomic and phenotypic detection technologies, the system can provide results from a positive blood culture sample in approximately five hours. Accelerate Diagnostics primarily serves markets in the United States, Europe, and the Middle East, aiming to improve patient outcomes by facilitating timely and accurate diagnosis of healthcare-associated infections.

BioVersys AG is a biopharmaceutical company based in Basel that specializes in the research and development of innovative drugs aimed at overcoming drug resistance in bacterial pathogens. The company is dedicated to addressing the pressing global health challenge of multidrug-resistant bacterial infections by restoring the effectiveness of existing antibiotics. BioVersys utilizes its proprietary TRIC (Transcriptional Regulator Inhibitory Compounds) technology platform to discover new therapies that inhibit bacterial resistance mechanisms. This approach not only targets novel bacterial pathways but also provides healthcare professionals with new treatment options for patients suffering from life-threatening infections caused by resistant bacterial strains.

Snipr Biome ApS is a biotechnology company based in Copenhagen, Denmark, focusing on the development of CRISPR technology for the treatment of microbial diseases. Established in 2017, the company aims to revolutionize how such diseases are addressed by leveraging the adaptive immune system to create medicines that selectively target and eliminate harmful bacteria based on their specific DNA sequences. By utilizing a novel approach that subverts elements of the endogenous bacterial CRISPR machinery, Snipr Biome provides health professionals with innovative tools for targeted microbiome engineering, enhancing the precision and effectiveness of treatments for bacterial infections.

Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company based in Basel, Switzerland, that focuses on developing innovative therapeutic products in the fields of oncology and anti-infectives. The company offers isavuconazole, marketed under the brand name Cresemba, an antifungal drug used to treat invasive aspergillosis and mucormycosis. Additionally, Basilea provides ceftobiprole, an intravenous antibiotic for community and hospital-acquired pneumonia, which is also undergoing Phase III clinical trials for other serious bacterial infections. The company is actively developing several candidates, including Derazantinib, for intrahepatic cholangiocarcinoma, and BAL101553 and BAL3833, which target various tumor types and cancer pathways. Through its integrated research and commercial operations, Basilea aims to address the growing challenges of antibiotic resistance and the limitations of current treatment options.

Summit Therapeutics Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. The company focuses on treating Clostridium difficile infection (CDI), with its lead product candidate, ridinilazole, currently in Phase III clinical trials. In addition to ridinilazole, Summit Therapeutics is developing the DDS-01 series aimed at treating infections caused by Neisseria gonorrhoeae and the DDS-04 series for Enterobacteriaceae. The company operates primarily in the United States, Latin America, and Europe, with the intention of establishing new standards of care for patients while creating value for payors and healthcare providers. Founded in 2003, Summit Therapeutics is positioned to address critical needs in the field of infectious diseases.

SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease.

Phico Therapeutics Limited is a biotechnology company based in Bourn, United Kingdom, focused on developing innovative antibiotics to combat antibacterial resistance. Utilizing its SASPject platform, the company delivers anti-bacterial proteins, including small acid-soluble spore proteins, to specific bacterial species through targeted non-delivery vehicles. Phico's product pipeline includes SASPject PT3, an antibiotic aimed at Pseudomonas aeruginosa; SASPject PT4 and PT5, designed for systemic use against Klebsiella pneumonia and Escherichia coli; and SASPject PT1.2, which targets Staphylococcus aureus. Additionally, the company is developing an intravenous-engineered bacteriophage drug intended to treat ventilator-associated pneumonia by using engineered bacterial viruses along with antibacterial proteins to inhibit bacterial reproduction and toxin release. Founded in 2000, Phico Therapeutics is committed to advancing solutions for pressing healthcare challenges posed by antibiotic resistance.

Novel Microdevices, LLC is focused on developing handheld devices for molecular diagnostics, specifically through its product, NOVEL DX. This innovative device utilizes microfluidics technology to analyze raw biological samples directly at the point of care, providing results in just 30 minutes. By enabling healthcare professionals to achieve lab-quality results without the need for a traditional laboratory setting, the device addresses various sectors including clinical diagnostics, biodefense, food safety, forensics, drug discovery, animal care, and agriculture. Founded in 2014 by Andrea Pais, Novel Microdevices is headquartered in Baltimore, Maryland.

The Jenner Institute was founded in November 2005 to develop innovative vaccines against major global diseases. Uniquely it focuses both on diseases of humans and livestock and tests new vaccine approaches in parallel in different species. A major theme is translational research involving the rapid early-stage development and assessment of new vaccines in clinical trials. The Institute comprises the research activities of over 30 Jenner Investigators who head leading research groups spanning human and veterinary vaccine research and development. Together the Institute Investigators comprise one of the largest non-profit sector research and development activities in vaccinology. Jenner Institute Investigators, through the support of many funders, are developing new vaccine candidates against major global infectious diseases. New vaccines against malaria, tuberculosis and HIV are currently in field trials in the developing world. Research is also underway on livestock vaccines against foot and mouth disease, avian influenza, bovine tuberculosis and other major causes of economic loss.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing innovative vaccines using its proprietary Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins into a single vaccine, thereby enhancing immune responses against a variety of infectious diseases affecting both children and adults. Affinivax targets several significant pathogens, including Streptococcus pneumoniae, bacterial nosocomial infections, Salmonella typhi, and Staphylococcus aureus. The company aims to create vaccines that not only provide broader disease coverage compared to existing options but also address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from the expertise of leading professionals in infectious diseases and vaccines, and it has received backing from the Bill & Melinda Gates Foundation, along with an exclusive license from Boston Children’s Hospital for its MAPS technology.

GlaxoSmithKline is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. The company aims to bring differentiated, high-quality and needed healthcare products to as many people as possible, with its 3 global businesses, scientific and technical know-how, and talented people. GSK's Pharmaceuticals business has a broad portfolio of innovative and established medicines with commercial leadership in respiratory and HIV. Our R&D approach focuses on science related to the immune system, the use of genetics, and advanced technologies. The Vaccines business has a broad portfolio and innovative pipeline of vaccines to help protect people throughout life. It delivers over two million vaccine doses per day to people living in over 160 countries. The Consumer Healthcare business develops and markets an innovative portfolio of consumer preferred and expert-recommended brands in the Pain relief, Respiratory, Digestive health, Oral Health, Nutrition, and Skin health categories.

Institute for Molecular Bioscience is a research institute at The University of Queensland.

Avails Medical, Inc. is an in vitro diagnostics company based in Menlo Park, California, focused on addressing antibiotic resistance and healthcare-associated infections. Founded in 2013, the company has developed an innovative electronic biosensor technology that enables rapid and accurate detection of infections across various bodily fluids. This technology provides real-time information on antibiotic sensitivity and resistance, allowing healthcare providers to optimize treatment at the point of prescription. Avails Medical's flagship product, eQuant, is a compact instrument that integrates a cuvette with an electrical sensor to analyze diluted blood samples. By facilitating diagnostic-guided therapy, the company's platform significantly reduces the time to treatment from days to minutes, thereby transforming the infection detection landscape and addressing a critical global health challenge.

Lumen Bioscience, Inc. is a biotechnology company based in Seattle, Washington, that focuses on developing therapeutic biologics for oral delivery. Founded in 2017, the company utilizes Spirulina, a blue-green algae, as a platform for the industrial-scale production of high-value molecules. Lumen Bioscience aims to create biologic drugs more efficiently than traditional methods, offering potential advancements in speed, scalability, and cost-effectiveness. The company serves various industries, including food, cosmetics, and healthcare, and is engaged in areas such as synthetic biology, protein design, immunology, bioreactor engineering, and cell physiology. By addressing prevalent diseases that currently lack effective treatments, Lumen Bioscience seeks to provide clinicians with innovative therapeutic options.

Spexis AG is a clinical-stage biopharmaceutical company based in Switzerland that specializes in the discovery and development of antibiotics and other specialized pharmaceutical products aimed at severe or life-threatening diseases. Founded in 1996, the company is focused on addressing high unmet medical needs, particularly in the realm of antibiotic resistance and severe respiratory conditions. Spexis's lead product, murepavadin, is currently in Phase III development, targeting Pseudomonas aeruginosa, which has been classified as a critical priority pathogen by the World Health Organization. The company's operations are centered on research, development, and the prospective commercialization of respiratory therapeutics.

The Helmholtz Centre for Infection Research applies basic research findings to medical applications. The company's goal is to lay the groundwork for new diagnostic tools, drugs, and therapies for infectious diseases. It researches pathogens that are medically important or can be used as models for infection research. Understanding these mechanisms will aid in the development of new drugs and vaccines to combat infectious diseases.

Vaxcyte, Inc. is a biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases globally. The company’s lead candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine. Additionally, Vaxcyte is advancing VAX-XP, which targets emerging strains that contribute to invasive pneumococcal disease and antibiotic resistance. Other notable candidates include VAX-A1, designed to protect against Group A Streptococcus infections, and VAX-PG, a therapeutic vaccine aimed at treating periodontal disease caused by Porphyromonas gingivalis. Vaxcyte utilizes a proprietary cell-free protein synthesis platform that enables the creation of protein carriers and antigens, enhancing vaccine development beyond conventional methods. Founded in 2013 and headquartered in Foster City, California, the company was previously known as SutroVax, Inc. before rebranding in May 2020.

Clarametyx Biosciences, Inc. is a biotechnology company based in Columbus, Ohio, focused on developing targeted and immune-enabling biologic therapies to address persistent infections linked to biofilms. Founded in 2020, the company utilizes a novel technology platform designed to penetrate the protective layers surrounding bacteria, facilitating immune responses and enhancing the effectiveness of antibiotic interventions. Among its key developments is CMTX-001, a humanized monoclonal antibody currently in preclinical stages aimed at treating hospital-acquired pneumonia. Clarametyx's innovative approach seeks to combat life-threatening infections while addressing the growing concerns of antibiotic resistance.

Locus Biosciences is focused on developing a CRISPR-engineered platform aimed at transforming the treatment of bacterial diseases. This innovative platform integrates CRISPR-Cas3 technology with bacteriophage, which are viruses that specifically target and eliminate pathogenic bacteria. By leveraging this combination, Locus Biosciences enables healthcare providers to initiate treatment more rapidly, ultimately leading to improved medical outcomes for patients. The company's approach is designed to offer a precise and effective solution for addressing bacterial infections.

Cellics is committed to saving lives and improving patients’ health using innovative biomimetic nanomedicines. It was created with the goal of applying Nanosponge Technology to treat and prevent diseases. It aims to employ innovative biomimetic nanomedicines to address serious diseases with a high unmet medical need. The company’s initial primary focus is on autoimmune and inflammatory diseases and difficult to treat infectious diseases. Additionally, Cellics is seeking to develop best-in-class vaccines for various diseases. The company is currently on schedule to advance its lead product candidate CTI-005 to human clinical trials for the treatment of bacterial pneumonia. It is the passion and goal of Cellics to use advanced technology to help human beings live healthier and longer lives. The company was founded in 2014 and is headquartered in San Diego, California.

Spexis AG is a clinical-stage biopharmaceutical company based in Switzerland that specializes in the discovery and development of antibiotics and other specialized pharmaceutical products aimed at severe or life-threatening diseases. Founded in 1996, the company is focused on addressing high unmet medical needs, particularly in the realm of antibiotic resistance and severe respiratory conditions. Spexis's lead product, murepavadin, is currently in Phase III development, targeting Pseudomonas aeruginosa, which has been classified as a critical priority pathogen by the World Health Organization. The company's operations are centered on research, development, and the prospective commercialization of respiratory therapeutics.

GlaxoSmithKline is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. The company aims to bring differentiated, high-quality and needed healthcare products to as many people as possible, with its 3 global businesses, scientific and technical know-how, and talented people. GSK's Pharmaceuticals business has a broad portfolio of innovative and established medicines with commercial leadership in respiratory and HIV. Our R&D approach focuses on science related to the immune system, the use of genetics, and advanced technologies. The Vaccines business has a broad portfolio and innovative pipeline of vaccines to help protect people throughout life. It delivers over two million vaccine doses per day to people living in over 160 countries. The Consumer Healthcare business develops and markets an innovative portfolio of consumer preferred and expert-recommended brands in the Pain relief, Respiratory, Digestive health, Oral Health, Nutrition, and Skin health categories.

Mutabilis SAS is a biopharmaceutical company based in Romainville, France, founded in 2001. The company specializes in the research and development of innovative anti-infective treatments aimed at addressing the challenges posed by multidrug-resistant Gram-negative bacterial infections. Mutabilis is engaged in discovering new therapeutic targets and developing a novel class of drugs to combat severe and nosocomial infections. Its portfolio includes antibacterials, vaccines, and other anti-infective agents, with a focus on applications in human health, immunology, allergology, hematology, and infectiology. As of June 2009, Mutabilis operates as a subsidiary of Pharma Omnium International SAS.

MicuRx Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing antibiotics to address drug-resistant bacterial infections. Founded in 2007 and headquartered in Palo Alto, California, the company has established a hybrid business model that leverages U.S. research and development alongside cost-effective scientific resources in China. MicuRx's product lineup includes MRX-I, an oral antibiotic targeting multi-drug resistant gram-positive pathogens, and its intravenous prodrug form, MRX-IV. Additionally, the company offers MRX-V, an injectable antibiotic for gram-negative bacteria, and MRX-VIII, a polymyxin for gram-negative infections. The company is also working on a pipeline of antibacterial drugs aimed at combating both gram-positive and gram-negative bacterial pathogens. MicuRx's subsidiary, Shanghai MicuRx, is responsible for commercializing its agents in China while global clinical studies continue.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

ContraFect is a biotechnology company pioneering the use of monoclonal antibodies to treat life-threatening infectious diseases. It addresses multi-drug resistant infections using therapeutic products from its lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. Its novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills bacteria. The company was founded in 2008 and is headquartered in Yonkers, New York.

Vaxdyn specializes in the development of vaccines and immunotherapies aimed at preventing infectious diseases, particularly those caused by antibiotic-resistant pathogens. The company employs innovative technologies, including antigens, immunomodulators, nanoparticles, and monoclonal antibodies, to create effective vaccines that help mitigate the impact of these drug-resistant infections on public health. Vaxdyn addresses customer inquiries through various channels, including phone, email, and online applications, ensuring accessible communication regarding their offerings.

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

Amicrobe, Inc.​ is an advanced biomaterials company with innovative product candidates designed to prevent and treat infections. The Company’s new, synthetic block copolypeptides (A-Blocks) are engineered to provide broad antimicrobial activity and superior tissue coverage when our natural barriers of defense are broken in surgery, trauma / burns, and diabetic foot ulcers.

Institute for Molecular Bioscience is a research institute at The University of Queensland.

Microbion Corporation is a biopharmaceutical company focused on developing therapeutics for resistant and difficult-to-treat infections. Founded in 1982 and headquartered in Bozeman, Montana, with an additional office in Vancouver, Canada, the company specializes in bismuth-thiols, which are designed to prevent microbial biofilms from forming on implanted medical devices and to manage biofilms in various infectious diseases. Microbion's product pipeline includes treatments for chronic and acute wound infections, particularly those related to diabetic foot ulcers, orthopedic implant-related infections, and other chronic wounds. The company also addresses the challenges posed by antibiotic-resistant microbes, including methicillin-resistant staphylococcus aureus, and aims to reduce infections associated with military wounds.

Day Zero Diagnostics Inc. is an infectious disease diagnostics company focused on developing rapid, sequencing-based diagnostics that identify bacterial pathogens and their antibiotic resistance profiles. The company employs advanced technologies such as Blood2Bac, which enhances bacterial DNA recovery from clinical samples, and BacDetect, designed for the swift detection of bacterial DNA. Its Keynome ID algorithm classifies bacterial species, while Keynome g-AST utilizes machine learning for genomic antibiotic susceptibility testing. Additionally, Day Zero maintains MicrohmDB, a comprehensive database that integrates whole genome sequencing data with resistance and susceptibility profiles of clinically relevant pathogens. Founded in 2016 and based in Boston, Massachusetts, Day Zero aims to transform infectious disease diagnostics by providing complete diagnoses—including species identification and antibiotic resistance—within hours, significantly improving treatment outcomes and reducing costs associated with prolonged diagnostic processes.

Module Innovations is a healthcare solutions provider focused on enhancing disease management for infectious diseases and antimicrobial resistance. The company has developed a portable and affordable point-of-care diagnostic platform that offers rapid, real-time information to improve clinical outcomes. Its initial products specifically target pathogens responsible for urinary tract infections (UTIs), such as E. coli, Klebsiella, Pseudomonas, and Enterococci, enabling quick pathogen identification and antibiotic susceptibility testing. Utilizing patented SDSAN technology, Module Innovations delivers UTI identification results in just 15 minutes and antibiotic susceptibility information within two hours. This innovative approach aims to facilitate informed decision-making for clinicians and provide faster outcomes for patients, making it a valuable tool in both clinical and home testing environments.

Lytica Therapeutics, Inc. is a biotechnology company focused on developing novel peptide therapeutics.

Facile Therapeutics is a biotechnology company that develops therapeutic drugs for clostridium difficile infection. The company demonstrated Ebselen, an anti-toxin that doesn't cause the death of healthy gut bacteria that makes the colon resistant to C diff reinfection. Facile Therapeutics was founded in 2017 by Marc Navre and Matthew Bogyo and is based in Belmont, California.

Pattern Bioscience, operating as Klaris Diagnostics, is a clinical diagnostics company focused on addressing antibiotic resistance. Founded in 2014 and based in Austin, Texas, the company has developed a next-generation clinical microbiology platform utilizing patented phenotypic single-cell technology. This innovative platform, known as Digital Culture technology, facilitates rapid pathogen identification and antibiotic susceptibility testing, providing results within hours rather than days. By integrating single-cell analysis with artificial intelligence pattern recognition, Pattern Bioscience bypasses traditional culture steps, leading to a more comprehensive and reliable diagnosis that encompasses all potential resistance mechanisms. This approach aims to enhance diagnostic accuracy and speed, significantly improving patient care in the face of growing concerns about antibiotic resistance.

Centauri Therapeutics is a biotechnology company focused on the discovery and development of innovative immunotherapeutics aimed at treating life-threatening diseases. The company employs its proprietary Alphamer technology, which utilizes chemically synthesized molecules to redirect naturally occurring antibodies towards specific pathogens, enhancing the body's immune response to fight infections. Centauri's approach features a dual mechanism of action: a moiety that directly targets cell surface antigens and a glycan effector domain that activates a robust pre-existing polyclonal immune response. This response facilitates cell death through mechanisms such as complement fixation, antibody-dependent cellular cytotoxicity, and phagocytosis by myeloid cells. Centauri has produced promising pre-clinical data, showcasing significant enhancements in complement fixation and opsonophagocytosis for both anti-bacterial and oncology therapeutics, along with in vivo proof of concept data across multiple infection models.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

The University of Queensland (UQ), established in 1909 and located in Brisbane, Australia, is a prominent public research university known for its commitment to knowledge leadership and quality education. It consistently ranks among the world's top universities and has received more national teaching awards than any other Australian institution. UQ serves approximately 53,600 students across its three campuses, offering a wide range of degree programs, including associate, bachelor, master, and doctoral degrees. The university aims to empower its students to drive positive societal change through innovative research and teaching excellence.

HelixBind is a biotechnology company located in Worcester, Massachusetts, founded in 2012. The company specializes in developing a pathogen identification platform that focuses on detecting bloodstream infections. This innovative platform enables rapid and precise identification of pathogens directly from whole blood specimens, eliminating the need for traditional blood culture methods. By facilitating swift detection, HelixBind's technology allows physicians to promptly implement targeted antimicrobial treatments and effectively monitor their efficacy throughout patient care.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

Venatorx Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery and development of novel anti-infective agents aimed at treating multi-drug-resistant bacterial infections and challenging viral infections. Founded in 2010 and based in Malvern, Pennsylvania, the company specializes in developing antibacterial drugs to combat resistant infections commonly encountered in hospital and community settings, such as those caused by MRSA, Pseudomonas spp., and Salmonella spp. Venatorx employs innovative chemical approaches to create treatments that exhibit selective and potent activity against various resistant bacterial strains, thereby providing healthcare professionals with broader treatment options to address significant unmet medical needs.

Techulon is a biotech firm located in Blacksburg, Virginia. Their headquarters and laboratories are located in the Virginia Tech Corporate Research Center, and their products derive from patents that we license from Virginia Tech. Their main laboratory is outfitted with equipment for the development, manufacture and commercialization of biopolymers applicable to research, therapeutics, energy and sustainability.

BioVersys AG is a biopharmaceutical company based in Basel that specializes in the research and development of innovative drugs aimed at overcoming drug resistance in bacterial pathogens. The company is dedicated to addressing the pressing global health challenge of multidrug-resistant bacterial infections by restoring the effectiveness of existing antibiotics. BioVersys utilizes its proprietary TRIC (Transcriptional Regulator Inhibitory Compounds) technology platform to discover new therapies that inhibit bacterial resistance mechanisms. This approach not only targets novel bacterial pathways but also provides healthcare professionals with new treatment options for patients suffering from life-threatening infections caused by resistant bacterial strains.

Trellis Bioscience develops a technology platform for cellular informatics. The company's technology has applications in the discovery and production of therapeutic monoclonal antibodies. Its cell biology platform provides a direct readout at the single cell level for monitoring activity of diverse cell types and quantifying the impact of potential therapeutic interventions. The company is based in San Francisco, California.

Procarta Biosystems Ltd., established in 2007 by the scientific founders, Dr. Michael McArthur and Professor Mervyn Bibb, is a spin-out company from the John Innes Centre, Norwich, a world renowned scientific centre of excellence in plant science and microbiology. The company was initially established through Plant Bioscience Ltd (PBL), the internationally regarded group specialising in early stage technology investment and IP management, on behalf of the JIC, the Sainsbury Laboratory and the Biotechnology and Biological Sciences Research Council. Procarta received seed funding in 2008 from the Rainbow and Iceni Seedcorn Funds and is currently headquartered on the Norwich Research Park.

Vaxxilon AG is focused on the discovery and development of innovative synthetic carbohydrate vaccines. Headquartered near Basel, Switzerland with research labs in Berlin, the Vaxxilon team is advancing several vaccine candidates for the prevention of major infectious diseases.

Integrated BioTherapeutics is a biotechnology company that focuses on discovering novel vaccines and therapeutics for emerging infectious diseases. Its antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines, and a variety of other product candidates for emerging viruses.

Debiopharm Group is a biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. They develop their products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

Idorsia Ltd is a biopharmaceutical company based in Allschwil, Switzerland, focused on discovering, developing, and commercializing innovative medicines for unmet medical needs. Established in 2017, the company specializes in small molecule therapies and has a diverse clinical pipeline targeting various therapeutic areas, including central nervous system disorders, cardiovascular conditions, immunological diseases, and orphan diseases. Idorsia collaborates with several partners, including Janssen Biotech for the development of aprocitentan, ReveraGen for vamorolone in Duchenne muscular dystrophy, and Hoffman-La Roche for cancer immunotherapy compounds. Additionally, partnerships with Antares Pharma and Neurocrine Biosciences aim to advance self-administered drug delivery systems and treatments for epilepsy, respectively. The company is committed to expanding therapeutic options and improving patient outcomes through its innovative research and development efforts.

ContraFect is a biotechnology company pioneering the use of monoclonal antibodies to treat life-threatening infectious diseases. It addresses multi-drug resistant infections using therapeutic products from its lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. Its novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills bacteria. The company was founded in 2008 and is headquartered in Yonkers, New York.

Spexis AG is a clinical-stage biopharmaceutical company based in Switzerland that specializes in the discovery and development of antibiotics and other specialized pharmaceutical products aimed at severe or life-threatening diseases. Founded in 1996, the company is focused on addressing high unmet medical needs, particularly in the realm of antibiotic resistance and severe respiratory conditions. Spexis's lead product, murepavadin, is currently in Phase III development, targeting Pseudomonas aeruginosa, which has been classified as a critical priority pathogen by the World Health Organization. The company's operations are centered on research, development, and the prospective commercialization of respiratory therapeutics.

ContraFect is a biotechnology company pioneering the use of monoclonal antibodies to treat life-threatening infectious diseases. It addresses multi-drug resistant infections using therapeutic products from its lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. Its novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills bacteria. The company was founded in 2008 and is headquartered in Yonkers, New York.

Forge Therapeutics, Inc. is a biotechnology company focused on discovering and developing innovative therapeutics, particularly novel antibiotics. The company employs a proprietary chemistry platform that targets metalloproteins, specifically metalloenzymes, to create selective inhibitors. By utilizing a combination of bioinorganic and medicinal chemistry, Forge aims to address the challenge of multi-drug resistant bacteria. Its approach allows for the development of small molecule inhibitors that can influence various biochemical processes, providing healthcare professionals with new tools to combat resistant infections effectively.

SciBac Inc. develops innovative live biotherapeutics aimed at treating antibiotic-resistant diseases while strengthening the microbiome. Founded in 2015 and located in Milpitas, California, the company utilizes a patented MERGE platform that employs directed evolution to enhance the efficacy of beneficial microorganisms. SciBac's initial therapeutics focus on chronic infections associated with cystic fibrosis, targeting pathogens such as Pseudomonas, Staphylococcus, Burkholderia, and non-tuberculous mycobacteria (NTM). By safely transferring beneficial genetic traits, SciBac's approach aims to promote rapid recovery and minimize the risk of reinfections, thereby improving treatment outcomes for patients facing these challenging infections.

Summit Therapeutics Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. The company focuses on treating Clostridium difficile infection (CDI), with its lead product candidate, ridinilazole, currently in Phase III clinical trials. In addition to ridinilazole, Summit Therapeutics is developing the DDS-01 series aimed at treating infections caused by Neisseria gonorrhoeae and the DDS-04 series for Enterobacteriaceae. The company operates primarily in the United States, Latin America, and Europe, with the intention of establishing new standards of care for patients while creating value for payors and healthcare providers. Founded in 2003, Summit Therapeutics is positioned to address critical needs in the field of infectious diseases.

BUGWORKS is a drug discovery company that aims to discover novel pharmaceutical assets for combating Antimicrobial Resistance (AMR). The company was founded in 2014 and is based in Bangalore, India.

Talis Biomedical Corporation is focused on transforming diagnostic testing through the development and commercialization of innovative products aimed at enabling accurate, low-cost, and rapid molecular testing for infectious diseases at the point of care. Founded in 2010 and based in Menlo Park, California, with an additional office in Chicago, Talis is advancing its Talis One platform, a compact, sample-to-answer, cloud-enabled molecular diagnostic system. This platform is designed to facilitate point-of-care testing for various infectious diseases, including COVID-19, thereby improving accessibility and efficiency in healthcare settings such as senior care facilities and laboratories.

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company based in Morristown, New Jersey, specializing in the discovery, development, and commercialization of antibiotics aimed at treating bacterial infections. The company offers several products, including Baxdela, Vabomere, Orbactiv, and Minocin, which target acute bacterial skin infections and gram-negative pathogens. Melinta's mission is to address the urgent need for effective antibiotics to combat drug-resistant infections, a significant public health challenge. The company is actively advancing its late-stage investigational antibiotic, delafloxacin, currently in Phase 3 development for acute bacterial skin and skin structure infections. Additionally, Melinta is engaged in research aimed at developing new antibiotics to tackle resistant pathogens associated with serious hospital-acquired infections. Melinta Therapeutics maintains license agreements with several institutions, including Yale University and Wakunaga Pharmaceutical Co., Ltd., and is supported by investors such as Vatera Healthcare Partners and Warburg Pincus.

Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrum efficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance.

Idorsia Ltd is a biopharmaceutical company based in Allschwil, Switzerland, focused on discovering, developing, and commercializing innovative medicines for unmet medical needs. Established in 2017, the company specializes in small molecule therapies and has a diverse clinical pipeline targeting various therapeutic areas, including central nervous system disorders, cardiovascular conditions, immunological diseases, and orphan diseases. Idorsia collaborates with several partners, including Janssen Biotech for the development of aprocitentan, ReveraGen for vamorolone in Duchenne muscular dystrophy, and Hoffman-La Roche for cancer immunotherapy compounds. Additionally, partnerships with Antares Pharma and Neurocrine Biosciences aim to advance self-administered drug delivery systems and treatments for epilepsy, respectively. The company is committed to expanding therapeutic options and improving patient outcomes through its innovative research and development efforts.

Shionogi & Co Ltd is a pharmaceutical company that specializes in the manufacturing and distribution of both specialty and generic drugs, as well as diagnostic reagents and medical devices. The company is involved in various stages of drug development, including manufacturing, formulation, packaging, and analysis, which are integral to its commercialization research that extends from late-stage drug discovery to commercial production. Shionogi also emphasizes collaboration through partnerships and licensing agreements with academic institutions and venture companies to enhance its research and development efforts.

HelixBind is a biotechnology company located in Worcester, Massachusetts, founded in 2012. The company specializes in developing a pathogen identification platform that focuses on detecting bloodstream infections. This innovative platform enables rapid and precise identification of pathogens directly from whole blood specimens, eliminating the need for traditional blood culture methods. By facilitating swift detection, HelixBind's technology allows physicians to promptly implement targeted antimicrobial treatments and effectively monitor their efficacy throughout patient care.

T2 Biosystems, Inc. is an in vitro diagnostics company focused on developing advanced diagnostic products for detecting pathogens and biomarkers. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers rapid and accurate testing for various medical conditions directly from unpurified patient samples, including whole blood, plasma, and urine. Key products include the T2Dx Instrument for diagnosing sepsis and Lyme disease, the T2Candida Panel for identifying Candida species, and the T2Bacteria Panel for detecting bacterial pathogens linked to sepsis. Additionally, T2 Biosystems provides the T2Resistance Panel for identifying antibiotic resistance markers and is developing other diagnostic panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with organizations like Canon U.S. Life Sciences and Allergan Sales to enhance its testing capabilities. Founded in 2006 and based in Lexington, Massachusetts, T2 Biosystems aims to improve patient care and reduce healthcare costs through its innovative diagnostic solutions.

MicuRx Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing antibiotics to address drug-resistant bacterial infections. Founded in 2007 and headquartered in Palo Alto, California, the company has established a hybrid business model that leverages U.S. research and development alongside cost-effective scientific resources in China. MicuRx's product lineup includes MRX-I, an oral antibiotic targeting multi-drug resistant gram-positive pathogens, and its intravenous prodrug form, MRX-IV. Additionally, the company offers MRX-V, an injectable antibiotic for gram-negative bacteria, and MRX-VIII, a polymyxin for gram-negative infections. The company is also working on a pipeline of antibacterial drugs aimed at combating both gram-positive and gram-negative bacterial pathogens. MicuRx's subsidiary, Shanghai MicuRx, is responsible for commercializing its agents in China while global clinical studies continue.

Specific Diagnostics, LLC is a medical device company based in West Palm Beach, Florida, founded in 2011. The company specializes in developing solutions for the detection, identification, and antibiotic susceptibility testing of pathogens. Its flagship product, the Specific Reveal system, utilizes patented technology that incorporates a low-cost small molecule sensor. This system is designed to streamline workflows in clinical settings and accelerate the time required to obtain diagnostic results, ultimately enhancing patient care by providing timely and specific treatment options.

Zikani Therapeutics, Inc. is focused on developing and commercializing innovative therapeutics for patients facing limited treatment options. The company utilizes its TURBO-ZM platform to create novel ribosome modulating agents (RMAs) aimed at addressing a variety of conditions, including cystic fibrosis, familial adenomatous polyposis, APC mutant colon cancer, recessive dystrophic epidermolysis bullosa, rare cancers, and other rare genetic diseases. Additionally, Zikani is developing antibiotic compounds that target serious, multi-drug resistant gram-negative infections, an area where existing treatments are often inadequate. Founded in 2014 and initially known as Macrolide Pharmaceuticals, the company is headquartered in Watertown, Massachusetts. Through its advancements in synthetic chemistry and microbiology, Zikani Therapeutics seeks to enhance patient recovery and improve outcomes in challenging medical scenarios.

Curza is a small-molecule therapeutics company that has developed several structurally distinct classes of proprietary drugs focused on infectious diseases and oncology. Curza’s lead program is a new class of broad spectrum antibiotics, focused on ESKAPE pathogens and drug-resistant Gram-negative bacteria. Inspired by a natural product, this class targets an unexploited binding site of the bacterial ribosome. With ever increasing reports of resistance to frontline therapies addressing Gram-negative bacteria, there is a critical need for new therapies and new therapies that work in new ways. However, very little can be found in the development pipeline. As a result, Curza’s compounds are addressing a major unmet medical need.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

Integrated BioTherapeutics is a biotechnology company that focuses on discovering novel vaccines and therapeutics for emerging infectious diseases. Its antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines, and a variety of other product candidates for emerging viruses.

Amicrobe, Inc.​ is an advanced biomaterials company with innovative product candidates designed to prevent and treat infections. The Company’s new, synthetic block copolypeptides (A-Blocks) are engineered to provide broad antimicrobial activity and superior tissue coverage when our natural barriers of defense are broken in surgery, trauma / burns, and diabetic foot ulcers.

Entasis Therapeutics is a late-stage clinical biopharmaceutical company dedicated to developing innovative treatments for serious infections caused by multidrug-resistant Gram-negative bacteria, a growing global health concern. The company’s anti-infective discovery platform has led to a diverse pipeline of differentiated drug candidates, including ETX2514SUL and SUL-DUR, which target Acinetobacter baumannii, zoliflodacin for Neisseria gonorrhoeae, and ETX0282CPDP aimed at Enterobacterales. Additionally, ETX0462 is being developed to address infections caused by Pseudomonas. Through its focused efforts, Entasis Therapeutics aims to provide effective solutions for patients suffering from these challenging bacterial infections.